EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Mitigation of supply chain challenges in cell therapy manufacturing: perspectives from the cord blood alliance

Patrick Killela, Kieran Herrity, Ludwig Frontier, Roger Horton, Joanne Kurtzberg iD, Wouter Van't Hof iD

Stem Cells Translational Medicine · 2024

DOI: 10.1093/stcltm/szae048 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Stem Cells Translational Medicine, 2024. Verfasst von Patrick Killela und 5 weiteren Autor:innen. Beteiligte Einrichtung: Carolinas Cord Blood Bank, Duke University, Durham, NC, United States. Hauptthemen laut MEDLINE: Blood Banks, Cell- and Tissue-Based Therapy, Fetal Blood. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cellular therapies rely on highly specialized supply chains that often depend on single source providers. Public cord blood banks (CBB) manufacturing the first cell therapy to be highly regulated by the FDA and related international agencies are a prime example of being subject to this phenomenon. In addition to banking unrelated donor cord blood units for transplantation, CBBs also source and characterize starting materials for supply to allogeneic cell therapy developers that often employ customized technologies offered by just a small number of manufacturers. As such, these supply chains are especially sensitive to even minor changes which often result in potential major impacts. Regulations can shape supply chain efficiencies, both directly via the definition of restricted technology and process requirements and indirectly by steering strategic business decisions of critical supply or service providers. We present 3 current supply chain issues with different root causes that are swaying efficiencies in cord blood banking and beyond. Specifically, the shortage of Hespan, a common supplement used in cord blood processing, the decision by the provider to stop supporting medical device marking of the Sepax system broadly used in cord blood banking, and a new European ruling on phasing out plasticizers that are critical for providing flexibility to cord blood collection bags, are all threatening downstream supply chain issues for the biologics field. We discuss overcoming these hurdles through the prism of unified mitigation strategies, defined, and implemented by multi-factorial teams and stakeholders, to negotiate resolutions with providers and regulators alike.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood BanksCell- and Tissue-Based TherapyFetal BloodHumansCord Blood Stem Cell TransplantationUnited StatesUnited States Food and Drug Administration

Stichwörter der Autor:innen

cell and gene therapycord bloodshortagessupply chain

Autor:innen und Institutionen

  • Carolinas Cord Blood Bank, Duke University, Durham, NC, United States.
  • Office of Regulatory Affairs and Quality, School of Medicine, Duke University, Durham, NC, United States.
  • NHS Blood and Transplant, London, UK.
  • Macopharma, Atlanta, GA, United States.
  • Anthony Nolan, London, United Kingdom.
  • Cord Blood Association, Washington, DC, United States.

ORCID-Profile: Joanne Kurtzberg, Wouter Van't Hof

Zitieren

APA

Killela, P., Herrity, K., Frontier, L., Horton, R., Kurtzberg, J., & Van't Hof, W. (2024). Mitigation of supply chain challenges in cell therapy manufacturing: perspectives from the cord blood alliance. Stem Cells Translational Medicine. https://doi.org/10.1093/stcltm/szae048

Vancouver

Killela P, Herrity K, Frontier L, Horton R, Kurtzberg J, Van't Hof W. Mitigation of supply chain challenges in cell therapy manufacturing: perspectives from the cord blood alliance. Stem Cells Translational Medicine. 2024. doi:10.1093/stcltm/szae048

BibTeX
@article{Killela2024,
  author = {Killela, Patrick and Herrity, Kieran and Frontier, Ludwig and Horton, Roger and Kurtzberg, Joanne and Van't Hof, Wouter},
  title = {Mitigation of supply chain challenges in cell therapy manufacturing: perspectives from the cord blood alliance},
  journal = {Stem Cells Translational Medicine},
  year = {2024},
  doi = {10.1093/stcltm/szae048}
}
Kostenlos starten →